{{Rsnum
|rsid=61764370
|Gene=KRAS
|Chromosome=12
|position=25207290
|Orientation=minus
|GMAF=0.04362
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
|Gene_s=KRAS
}}{{PMID|21385923|OA=1
}} Contrary to the claims of a test being marketed, a large study (8,500+ patients and >10,000 controls) found no evidence for any association between [[rs61764370]] and any form of [[ovarian cancer]].

{{PMID Auto
|PMID=20676756
|Title=Prevalence of the variant allele rs61764370 T&gt;G in the 3'UTR of [[KRAS]] among Dutch [[BRCA1]], [[BRCA2]] and non-BRCA1/BRCA2 breast cancer families
|OA=1
}}

{{PMID Auto
|PMID=21435948
|Title=A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis
|OA=1
}}

This [http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70156-5/fulltext letter in the Lancet] challenges the claims of an association with triple-negative breast cancer in {{PMID|21435948|OA=1
}}

{{PMID Auto
|PMID=22679560
|Title=KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer
|OA=1
}}
{{PMID Auto
|PMID=20647319
|Title=A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.
|OA=1
}}

{{PMID Auto
|PMID=21807336
|Title=Association between KRAS rs61764370 and triple-negative breast cancer--a false positive?
}}

{{PMID Auto
|PMID=22003074
|Title=KRAS rs61764370 in Epithelial Ovarian Cancer-Letter.
}}

{{PMID Auto
|PMID=22584434
|Title=High Let-7a MicroRNA Levels in KRAS-Mutated Colorectal Carcinomas May Rescue Anti-EGFR Therapy Effects in Patients with Chemotherapy-Refractory Metastatic Disease.
|OA=1
}}

{{PMID Auto
|PMID=23167843
|Title=Let-7 miRNA-binding site polymorphism in the KRAS 3`UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab
|OA=1
}}

{{PMID Auto
|PMID=24282149
|Title=Targeted Knock-in of the Polymorphism rs61764370 does not Affect KRAS Expression but Reduces let-7 Levels
}}

{{PMID Auto
|PMID=23010532
|Title=No evidence for genetic association with the let-7 microRNA-binding site or other common KRAS variants in risk of endometriosis.
|OA=1
}}

{{PMID Auto
|PMID=23324806
|Title=The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients.
}}

{{PMID Auto
|PMID=25081901
|Title=A 3'UTR KRAS variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
}}

{{PMID Auto
|PMID=25183481
|Title=A let-7 microRNA-Binding Site Polymorphism in KRAS Predicts Improved Outcome in Patients with Metastatic Colorectal Cancer Treated with Salvage Cetuximab/Panitumumab Monotherapy
}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}